Joshua C Horan
Overview
Explore the profile of Joshua C Horan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
142
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin J, Horan J, Tangpeerachaikul A, Swalduz A, Valdivia A, Johnson M, et al.
Cancer Discov
. 2024 Sep;
14(12):2367-2386.
PMID: 39269178
Three generations of tyrosine kinase inhibitors (TKI) have been approved for anaplastic lymphoma kinase (ALK) fusion-positive non-small cell lung cancer. However, none address the combined need for broad resistance coverage,...
2.
Drilon A, Horan J, Tangpeerachaikul A, Besse B, Ou S, Gadgeel S, et al.
Cancer Discov
. 2022 Dec;
13(3):598-615.
PMID: 36511802
The combined preclinical features of NVL-520 that include potent targeting of ROS1 and diverse ROS1 resistance mutations, high selectivity for ROS1 G2032R over TRK, and brain penetration mark the development...
3.
Horan J, Kuzmich D, Liu P, Disalvo D, Lord J, Mao C, et al.
Bioorg Med Chem Lett
. 2015 Dec;
26(2):466-471.
PMID: 26687487
Poor solubility and cationic amphiphilic drug-likeness were liabilities identified for a lead series of S1P3-sparing, S1P1 agonists originally developed from a high-throughput screening campaign. This work describes the subsequent optimization...
4.
Horan J, Sanyal S, Choi Y, Hill-Drzewi M, Patnaude L, Anderson S, et al.
Bioorg Med Chem Lett
. 2014 Sep;
24(20):4807-11.
PMID: 25241927
The discovery of a new series of selective S1P1 agonists is described. This series of piperazinyl-oxadiazole derivatives was rapidly optimized starting from high-throughput screening hit 1 to afford potent and...
5.
Fryer R, Muthukumarana A, Harrison P, Mazurek S, Chen R, Harrington K, et al.
PLoS One
. 2013 Jan;
7(12):e52985.
PMID: 23285242
Sphingosine-1-phospate (S1P) and S1P receptor agonists elicit mechanism-based effects on cardiovascular function in vivo. Indeed, FTY720 (non-selective S1P(X) receptor agonist) produces modest hypertension in patients (2-3 mmHg in 1-yr trial)...
6.
Wender P, Horan J, Verma V
Org Lett
. 2006 Nov;
8(23):5299-302.
PMID: 17078702
[Structure: see text] The total synthesis and preliminary biological evaluation of the first bryostatin analogs (bryologs) to incorporate B-ring substitution are reported. Asymmetric syntheses of two new polyketide "spacer" domains...
7.
Wender P, Horan J
Org Lett
. 2006 Sep;
8(20):4581-4.
PMID: 16986955
The design, asymmetric synthesis, and biological evaluation of a new class of bryostatin analogues based on a pseudosymmetric spacer domain are described. An aryl bromide diversification site is incorporated allowing...
8.
Wender P, Baryza J, Brenner S, Clarke M, Craske M, Horan J, et al.
Curr Drug Discov Technol
. 2006 Feb;
1(1):1-11.
PMID: 16472215
Bryostatin 1 represents a novel and potent therapeutic lead with a unique activity profile. Its natural and synthetic availability is severely limited. Function oriented synthesis provides a means to address...
9.
Wender P, Clarke M, Horan J
Org Lett
. 2005 May;
7(10):1995-8.
PMID: 15876038
The syntheses of three newly designed bryostatin analogues are reported. These simplified analogues, which lack the A-ring present in the natural product but possess differing groups at C9, were obtained...
10.
Wender P, Baryza J, Bennett C, Bi F, Brenner S, Clarke M, et al.
J Am Chem Soc
. 2002 Nov;
124(46):13648-9.
PMID: 12431074
Macrocycle 1 is a new highly potent analogue of bryostatin 1, a promising anti-cancer agent currently in human clinical trials. In vitro, 1 displays picomolar affinity for PKC and exhibits...